An effective federal tax rate above seventy percent. That is roughly where a state-licensed cannabis business in America sits, and it is not the result of a tax on cannabis. There is no federal tax on cannabis.
It is the result of a single sentence in the tax code, and understanding that sentence explains why last week’s rulemaking is a business story rather than a drug policy one.
The Drug Enforcement Administration formally opened a rulemaking to move marijuana from Schedule I to Schedule III of the Controlled Substances Act. This is a profile of what a schedule actually is, because the word suggests a ranking of danger and the consequences are almost entirely elsewhere.
What the schedules are
Five categories, created in 1970, into which every controlled substance is placed. The criteria are a substance’s potential for abuse, whether it has an accepted medical use, and the safety of its use under medical supervision.
Schedule I is defined as high potential for abuse, no currently accepted medical use, and no accepted safety even under supervision. That has been the classification since 1970.
Schedule III is a different set of findings: potential for abuse lower than Schedules I and II, a currently accepted medical use, and moderate to low physical dependence.
The finding that matters legally is the middle one. Moving to Schedule III is the federal government stating that there is an accepted medical use, which is a factual determination about a substance rather than a policy preference about it.
What a schedule does not do
It does not legalize anything, and this is where almost all the coverage goes wrong.
Schedule III substances are prescription medicines, dispensed through pharmacies against a prescription from a licensed practitioner, manufactured in registered facilities. A state dispensary selling to an adult with an identification card does not become a lawful Schedule III operation. It remains a federal violation.
Rescheduling changes the classification of the substance. It does not change the status of the industry that sells it, which continues to exist in the gap between state law and federal law exactly as it has since 1996.
The sentence that does the work
Section 280E of the Internal Revenue Code. It was written in 1982, after a convicted cocaine trafficker successfully deducted his business expenses on his tax return, and Congress decided that should not be possible.
It provides that no deduction or credit is allowed for a business trafficking in controlled substances listed in Schedule I or Schedule II.
Read that as an operator. A business may not deduct rent, payroll, marketing, utilities, insurance or professional fees. Cost of goods sold remains deductible, because that is a constitutional constraint rather than a legislative choice, but everything else does not.
So the business is taxed on something close to gross profit rather than on net income. A company with real margins can end up owing more federal tax than it made, which is how the effective rate gets above seventy percent and why so many licensed operators have never turned a profit.
Why Schedule III is the whole game
280E names Schedule I and Schedule II. It does not name Schedule III.
A substance moved to Schedule III falls outside the provision, and a business trafficking in it may deduct ordinary business expenses like any other business.
That is the entire commercial content of this rulemaking. Not access, not criminal law, not the state-federal conflict, none of which changes. A tax provision that was drafted with reference to two schedules stops applying because a substance moved to a third.
What the process requires from here
Rescheduling is not a decision somebody announces. It is a rulemaking under the Administrative Procedure Act, and the steps are fixed.
A notice of proposed rulemaking is published, a comment period runs, the agency reviews what it receives, and any person adversely affected may request a hearing before an administrative law judge. Only after all of that does a final rule issue, with its own effective date.
Each of those stages is a place where months are spent and where a record is built for the litigation that follows. The practical consequence is that nothing changes for anyone for a considerable time, and that the announcement and the effect are separated by a process most coverage treats as a formality.
What the object is actually for
Which is the useful way to think about the schedules generally, and the reason this profile is worth writing.
A schedule is described as a classification of danger. In practice it is a cross-reference, pointed at by a large number of other statutes and regulations that were each written for their own purposes: tax treatment, research licensing, prescribing authority, banking supervision, immigration consequences, employment testing rules.
None of those statutes decides anything about cannabis. They decide things about schedules, and the schedule decides about cannabis. Change the schedule and dozens of unrelated rules change at once, in ways nobody sat down and chose.
Research is the other large one. Schedule I research requires registrations and security arrangements that have made studying the substance genuinely difficult for fifty years, which produced a circular problem: no accepted medical use, because the research is hard, because there is no accepted medical use.
Banking is the other cross-reference worth naming. Financial institutions have largely declined to serve the industry because handling proceeds from a Schedule I substance carries money-laundering exposure, which is why a great deal of a multi-billion dollar business runs on cash. Rescheduling does not resolve that on its own, because the underlying federal illegality remains, but it removes one of the arguments a compliance department uses to say no.
What to watch
Not the political reaction, which is loud and changes nothing about the process.
Watch the comment period and then the administrative law judge. A rulemaking of this kind attracts a very large number of comments, and an objecting party can request a hearing, which adds months and produces a record that any subsequent court challenge will be built on.
Watch for litigation on the finding itself. The accepted-medical-use determination is the legally vulnerable part, and a challenge would argue the agency departed from the standard it has applied for decades.
Watch also for what the states do, because several have statutes and tax codes that reference the federal schedule directly, and a change at the federal level propagates into them automatically and in ways nobody drafted for.
Most of all, watch the tax year. If a final rule takes effect partway through one, whether 280E applies to the whole year or only part of it is worth more to most operators than every other question in the docket combined, and nothing published so far answers it.
